Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I-driven cancer immunotherapy
Aleksandr Barinov, Heidy Vera-Peralta, Joëlle S. Nader, Valérie Najburg, Chantal Combredet, Atousa Arbabian, Ségolène Gracias, Phanramphoei Namprachan Frantz, Roseline Vibert, Eddy Simard, Marie Coateval, Daniel Pouliquen, Tacien Petithomme, Matthieu Prot, Etienne Simon‐Lorière, , Frédéric Tangy
This paper modifies a measles vaccine by removing a viral protein to create a cancer immunotherapy that activates the immune system via RIG-I signaling, leading to tumor regression in multiple models.
bioRxiv · Oct 3, 2025 · PreprintImmunology